TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3334108
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg twice daily
Study: 30775427
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 mcg twice daily
Study: 30775427
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 50 mcg twice daily
Study: 30775427
Drug: Tiotropium (TIO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO; 18 mcg once daily)
Study: 27609033
Drug: sWBV (side-alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: sWBV (side-alternating whole body vibration) for 14 weeks with ten 9-minute sessions weekly
Study: 16572920
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg test formulation
Study: 7914759
Drug: Oral sulphasalazine
Normalized name: sulfasalazine Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulphasalazine (2g/day)
Study: 3053176
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose warfarin (mean daily dose of 4.6 mg)
Study: 29072166
Drug: Protein rich
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein rich meal during each treatment in the intervention group (IG)
Study: 23380567
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily for 4 weeks
Study: 23380567
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg daily for 4 weeks
Study: 20156334
Drug: Phytalgic (food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytalgic (food supplement containing fish oils, urtica dioica, zinc, and vitamin E)
Study: 10383925
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 500 mg bosentan (3.7 MBq)
Study: 10383925
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of 250 mg bosentan (3.7 MBq)
Study: 2679831
Drug: diazepam 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 35 mg
Study: 2679831
Drug: diazepam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (both doses)
Study: 9125
Drug: Oxypertine 20
Normalized name: oxypertine
DrugBank: Oxypertine (DB13403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxypertine 20 mg orally as a nocturnal sedative and again on the morning of operation
Study: 9125
Drug: Papaveretum 10
Normalized name: papaveretum 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 10 mg
Study: 31092024
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone (EPI group; n = 18)
Study: 31092024
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (IV group; n = 12)
Study: 28692172
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 100,000 IU monthly
Study: 28692172
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 100,000 IU monthly (with baseline 25-hydroxyvitamin D ≤ 30 nmol L-1)
Study: 28692172
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 100,000 IU monthly (with baseline 25-hydroxyvitamin D > 30 nmol L-1)
Study: 8470626
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole plus 4 x 500 mg amoxicillin suspension for 1 wk (group I, n = 35)
Study: 8470626
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 40 mg omeprazole plus 4 x 500 mg amoxicillin for 1 wk (group II, n = 50)
Study: 8470626
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20 mg omeprazole plus 4 x 500 mg amoxicillin for 2 wk (group III, n = 62)
Study: 8470626
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20 mg omeprazole (day 1‐14) and 4 x 500 mg amoxicillin (day 8‐14) (group IV, n = 22)
Study: 8470626
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20 mg omeprazole for 2 wk (group V, n = 11)
Study: 3512149
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nalbuphine
Study: 3512149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nalbuphine and acetaminophen
Study: 26967465
Drug: Low-magnitude, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-magnitude, high-frequency mechanical stimulation (0.3 g; 32-37 Hz) for 2 sessions lasting 10 minutes each, 7 days per week for 1 year.
Study: 24973176
Drug: Esophageal capsule
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal capsule esophagoscopy (ECE)
Study: 22616061
Drug: Multiple zygomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple zygomatic implants (Zyg); 28 zygomatic and 5 standard implants placed.
Study: 22616061
Drug: Standard implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implants (Stand); 41 standard implants placed, 3 lost.
Study: 18328120
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/HCTZ 12.5 mg
Study: 10584979
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg omeprazole
Study: 1862209
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of fluphenazine decanoate (5 to 10 mg every 2 weeks)
Study: 6352658
Drug: Ceftazidime 0.5
Normalized name: avibactam-ceftazidime 0.5 g-2 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 0.5 g every 12 h for 7 to 10 days
Study: 6352658
Drug: Tobramycin 1
Normalized name: tobramycin 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 1 mg/kg every 8 h for 7 to 10 days
Study: 24962473
Drug: Macitentan 30
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 30 mg loading dose on day 1 followed by 10 mg once daily for 3 days
Study: 24962473
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg three times a day for 3 days and a single 20 mg dose on day 4
Study: 21350044
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg oral nicotine lozenge
Study: 17333521
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin 10 mg once daily
Study: 17333521
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine 4 mg once daily
Study: 17333521
Drug: Immediate-release tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tolterodine 2 mg twice daily
Study: 15554600
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg for six months
Study: 9389845
Drug: 4% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% mepivacaine 80 mg
Study: 9389845
Drug: hyperbaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric 0.5% bupivacaine 10 mg
Study: 25546420
Drug: MABGEL (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABGEL (2.5 g of gel daily for 12 days containing 10 or 20 mg/g of each mAb)
Study: 20420544
Drug: Adjuvant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant medications (tricyclics and antiseizure)
Study: 7675045
Drug: Gluten-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten-free diet with oats (50 to 70 g per day from three sources: two types of wheat-starch flour mixed with oats, muesli containing 60% oats, rolled-oat breakfast cereal)
Study: 2301781
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (atropine sulfate and isoetharine)
Study: 7008147
Drug: Diazepam as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam as pre-medication
Study: 30681185
Drug: Teprenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone (150 mg/day) with long-term low-dose aspirin
Study: 30681185
Drug: Teprenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone (150 mg/day) with other NSAIDs
Study: 19034732
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) (40 mg)
Study: 10597880
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA (2.5 mg/day)
Study: 10597880
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + NG (0.05 mg/day)
Study: 8565031
Drug: Calcitonin salmon
Normalized name: Calcitonin Salmon
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin salmon nasal spray (200 IU/d)
Study: 8565031
Drug: Calcitonin salmon
Normalized name: Calcitonin Salmon
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin salmon nasal spray
Study: 2035326
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline (n = 11)
Study: 2035326
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 11)
Study: 28485777
Drug: 0.10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/kg vecuronium bromide combined with propofol and fentanyl
Study: 7308554
Drug: Betnovate (betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betnovate (betamethasone 17‐valerate, 0.1%) cream diluted to 50% in various vehicles
Study: 7308554
Drug: Other formulations
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other formulations tested
Study: 30557295
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient physical therapy (PT)
Study: 28209333
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) supplementation (0.9 g GTE per day for 12 months)
Study: 24154935
Drug: Linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 5mg once-daily
Study: 24154935
Drug: Linagliptin 2.5mg
Normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5mg twice-daily
Study: 21824990
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg titrated to 300 mg once daily after 3 months)
Study: 14676992
Drug: Estradiol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (50 microg transdermal 17beta‐estradiol)
Study: 9660986
Drug: Oral cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cimetidine
Study: 1251156
Drug: Bactrim (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bactrim (2 x 2 tablets or ampoules daily)
Study: 26589819
Drug: Lisinopril (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (n = 9,054)
Study: 24388839
Drug: Trimethoprim-sulfamethoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days, followed by tablet every 2 days
Study: 24388839
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet every 2 days
Study: 11701687
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 microg daily)
Study: 20406615
Drug: Cumulative glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative glucocorticoid dose
Study: 10333345
Drug: Glucose 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 20% infusion at 0.3, 1.0, and 3.0 ml/min for 5 min each
Study: 10333345
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% infusion
Study: 10333345
Drug: Glucose 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 20% infusion during local hyperinsulinaemia (insulin 0.05 mU/kg/min)
Study: 10333345
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% infusion during local hyperinsulinaemia
Study: 8983282
Drug: Cisplatin dose
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin dose adjustment to reach a target plasma concentration of total platinum (TP) of 2000 mu/l
Study: 8983282
Drug: Cisplatin without
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin without dose adjustment
Study: 8983282
Drug: Cisplatin dose
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin dose adjustment
Study: 1834864
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus flutamide (250 mg 3 times daily)
Study: 30580081
Drug: L-theanine (450–900
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (450–900 mg)
Study: 26791438
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment twice a week for 2 months
Study: 25247967
Drug: Thin-slice low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thin-slice low-dose CT measurements in airways with a luminal diameter of 5 to 10 mm
Study: 25247967
Drug: Thin-slice low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thin-slice low-dose CT measurements in airways with a luminal diameter of 10 mm or greater
Study: 18573585
Drug: omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 PUFAs 1.8 g/day
Study: 10863061
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (S alone)
Study: 9089857
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine and self-administration of 0.6 mg every 30 minutes
Study: 9089857
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of 3.75 mg of plain bupivacaine on request
Study: 9089857
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine
Study: 9089857
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with a continuous background infusion via microspinal catheters
Study: 9089857
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of bupivacaine
Study: 3510540
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with sympathomimetics and methylxanthines
Study: 26103979
Drug: Progressive spacing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive spacing of TNF-blocker injections (S-arm)
Study: 26103979
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of TNF-blocker injections (M-arm)
Study: 25793955
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of a mixture of probiotics in addition to brushing teeth and using fluoridated toothpaste.
Study: 23232966
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefazolin intramuscularly (reference group)
Study: 23232966
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of isotonic sodium chloride solution (study group)
Study: 18236391
Drug: FK (trough,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK (trough, 6‐10 ng/mL)
Study: 18236391
Drug: CsA (C2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (C2, 600‐1200 ng/mL)
Study: 16774104
Drug: Other clobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other clobetasol propionate preparations (solution, foam, cream, lotion, shampoo, emollient)
Study: 14660202
Drug: Fitness training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitness training added to treatment
Study: 14660202
Drug: Multifaceted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted treatment (without fitness training)
Study: 10741688
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (0.25 IU x kg per week)
Study: 8694313
Drug: Intravenous ondansetron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ondansetron, 0.15 mg/kg
Study: 1552202
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated trivalent cold-recombinant influenza vaccine (10^5 TCID50 of each strain)
Study: 1552202
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated trivalent cold-recombinant influenza vaccine
Study: 31430268
Drug: RPh201 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPh201 (20 mg) administered subcutaneously twice weekly
Study: 31430268
Drug: Placebo (cottonseed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cottonseed oil vehicle) administered subcutaneously twice weekly
Study: 28419650
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (solifenacin 5 mg/mirabegron 25 mg, increasing to 50 mg after week 4)
Study: 25304838
Drug: Butylscopolamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylscopolamine (20 mg intravenously immediately before the end of the operation)
Study: 25304838
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication for prevention of CRBD)
Study: 23720276
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of autologous BM-MNC
Study: 23720276
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramyocardial and intracoronary injection of autologous BM-MNC
Study: 17682094
Drug: Ceftaroline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline (600 mg every 12 h)
Study: 17682094
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (i.v. vancomycin 1 g every 12 h with or without adjunctive i.v. aztreonam 1 g every 8 h)
Study: 9421387
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg once daily)
Study: 7652582
Drug: INF-alpha therapy
Normalized name: r-INF-alpha
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INF-alpha therapy
Study: 7652582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INF-alpha therapy with other chemotherapeutic agents and/or biologicals
Study: 2673315
Drug: Felodipine (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (chronic oral treatment for 8 weeks)
Study: 2673315
Drug: Felodipine (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (acute intravenous administration)
Study: 2673315
Drug: Felodipine (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (chronic oral treatment)
Study: 790413
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine (5-20 mg)
Study: 790413
Drug: Depot fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot fluphenazine (25 mg/q 3 weeks)
Study: 790413
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and depot fluphenazine
Study: 790413
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and depot fluphenazine
Study: 790413
Drug: Dosage equivalence
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage equivalence
Study: 26235006
Drug: Adverse neurological
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse neurological event(s) during therapy
Study: 17965485
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel or ticlopidine (Group I, n=28)
Study: 17965485
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31)
Study: 11193233
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) oral suspension of 800 mg/d for 12 weeks
Study: 9777138
Drug: Hirulog and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog and aspirin before streptokinase
Study: 9777138
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with streptokinase